Macrogenics (MGNX) FCF Margin (2012 - 2026)
Macrogenics (MGNX) posted quarterly FCF Margin of 173.7% for Q1 2026, up 18441.0% year-over-year from N/an in Q1 2025, and down 266.64% quarter-over-quarter from 104.24% in Q4 2025.
Powered by 
Analysis
Macrogenics (MGNX) FCF Margin (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported FCF Margin for 15 consecutive years, with 173.7% the latest figure, recorded in Q1 2026.
- In Q1 2026, FCF Margin rose 18441.0% year-over-year to 173.7%; the TTM figure through Mar 2026 stood at 44.52% (down 249.0% YoY), while the FY2025 annual figure was 54.24%, down 618.0% from the prior year.
- FCF Margin slipped to 173.7% in Q1 2026 per MGNX's latest filing, from 104.24% in the prior quarter.
- Across five years, FCF Margin topped out at 104.24% in Q4 2025 and bottomed at 532.48% in Q1 2022.
- Historically, FCF Margin has averaged 177.72% across 5 years, with a median of 173.7% in 2026.
- Annual changes were most pronounced in 2023 — FCF Margin jumped 47937 bps — and 2024, when it sank 45090 bps.
- Macrogenics' FCF Margin stood at 39.57% in 2022, then slumped by 746 bps to 255.58% in 2023, then soared by 62 bps to 97.57% in 2024, then soared by 207 bps to 104.24% in 2025, then tumbled by 267 bps to 173.7% in 2026.
- Business Quant data shows MGNX's FCF Margin at 173.7% in Q1 2026, 104.24% in Q4 2025, and 41.41% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Macrogenics | 284.90 Mn | 171.00 Mn | - | -126.57% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -126.57% |
| Mar 31, 2026 | -174.03% |
| Dec 31, 2025 | 103.76% |
| Sep 30, 2025 | -42.03% |
| Jun 30, 2025 | -694.42% |
| Mar 31, 2025 | -359.45% |
| Dec 31, 2024 | -97.57% |
| Sep 30, 2024 | 53.81% |
| Jun 30, 2024 | -421.60% |
| Mar 31, 2024 | -517.38% |
| Dec 31, 2023 | -267.32% |
| Sep 30, 2023 | -343.80% |
| Jun 30, 2023 | -18.08% |
| Mar 31, 2023 | -53.85% |
| Dec 31, 2022 | 39.57% |
| Sep 30, 2022 | -24.50% |
| Jun 30, 2022 | -192.92% |
| Mar 31, 2022 | -532.48% |
| Dec 31, 2021 | -393.61% |
| Sep 30, 2021 | -108.08% |